2024-518101-18-02CompletedPhase 4
Exploring the Pharmacomicrobiomics of Depression
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Jan 2025
Brief summary (registry, in English)
The main aim of this project is to associate the gut microbial community and treatment efficacy (i.e., relieve in symptoms and side effects) in patients with depression.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 16 Jan 2025
- Start date
- 20 Oct 2024
- Lead sponsor
- Radboud universitair medisch centrum Stichting
- Diseases
- Depression
- EU CT number
- 2024-518101-18-02
- EudraCT number
- 2021-006510-36
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 25
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of antibiotics in a period of three months prior to the baseline visit
Other
- Currently pregnant or breastfeeding
Who the study is looking for
- Aged ≥ 18
- Main diagnosis of unipolar depression
- Indication for the prescription of an antidepressant
- Starting a new SSRI/SNRI or TCA antidepressant treatment
- Having already used one or more antidepressants without effect and/or with sideeffe
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboud universitair medisch centrum Stichting | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.